Beth C. Seidenberg - 13 Jul 2023 Form 3 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role
Director
Signature
/s/ Dennis Hom, Attorney-in-Fact
Issuer symbol
SGMT
Transactions as of
13 Jul 2023
Net transactions value
$0
Form type
3
Filing time
13 Jul 2023, 21:11:38 UTC
Previous filing
27 Jun 2023
Next filing
20 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SGMT Common Stock 38,763 13 Jul 2023 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SGMT Series A Preferred Stock 13 Jul 2023 Common Stock 6,781 See footnote F1, F2
holding SGMT Series B Preferred Stock 13 Jul 2023 Common Stock 6,208 See footnote F1, F2
holding SGMT Series B-1 Preferred Stock 13 Jul 2023 Common Stock 108,163 See footnote F1, F2
holding SGMT Series C Preferred Stock 13 Jul 2023 Common Stock 108,163 See footnote F1, F2
holding SGMT Series D Preferred Stock 13 Jul 2023 Common Stock 76,796 See footnote F1, F2
holding SGMT Series E Preferred Stock 13 Jul 2023 Common Stock 84,768 Direct F2, F3
holding SGMT Series E Preferred Stock 13 Jul 2023 Common Stock 1,297,549 See footnote F1, F2
holding SGMT Series F Preferred Stock 13 Jul 2023 Common Stock 257,052 See footnote F1, F2
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 23,216 $6.36 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
F2 Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a 79.4784-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock effected by the Issuer on July 7, 2023) at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering into the number of shares shown in column 3. The Preferred Stock has no expiration date.
F3 Shares held directly by the Reporting Person. Such shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee".
F4 The shares underlying this option are fully vested and exercisable as of the date hereof.

Remarks:

Exhibit 24 - Power of Attorney